Daptomycin for vancomycin-resistant enterococcal infection a review of the clinical effectiveness, cost-effectiveness and guidelines

Vancomycin-resistant enterococci (VRE) infections can mostly be treated with antibiotics other than vancomycin, and laboratory tests can be performed to identify optimal treatment regimens. Daptomycin is one antibiotic with known in vitro activity against VRE. Daptomycin and vancomycin have differen...

Full description

Bibliographic Details
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2016, 14 January 2016
Series:Rapid response report: summary with critical appraisal
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:Vancomycin-resistant enterococci (VRE) infections can mostly be treated with antibiotics other than vancomycin, and laboratory tests can be performed to identify optimal treatment regimens. Daptomycin is one antibiotic with known in vitro activity against VRE. Daptomycin and vancomycin have different bactericidal mechanisms of action; specifically, daptomycin works by binding or inserting into the outer membrane, while vancomycin inhibits cell wall synthesis. Other possible options for treating VRE include linezolid, tigecycline, oritavancin, televancin, and a combination of quinupristin and dalfopristin. This Rapid Response report aims to review the comparative clinical- and cost-effectiveness of daptomycin for patients with VRE infections. Evidence-based guidelines on the optimal use of daptomycin in patients with VRE infections will also be summarized
Physical Description:1 PDF file (22 pages) illustrations